Savara (NASDAQ:SVRA) Sees Large Volume Increase Following Insider Buying Activity

Shares of Savara Inc (NASDAQ:SVRA) saw unusually-high trading volume on Wednesday following insider buying activity. Approximately 5,254,916 shares traded hands during trading, an increase of 318% from the previous session’s volume of 1,257,429 shares.The stock last traded at $3.15 and had previously closed at $2.94.

Specifically, Director Joseph S. Mccracken purchased 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The shares were bought at an average price of $2.95 per share, for a total transaction of $59,000.00. Following the completion of the transaction, the director now owns 210,837 shares of the company’s stock, valued at approximately $621,969.15. This trade represents a 10.48 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link.

Analyst Ratings Changes

A number of research firms have recently weighed in on SVRA. HC Wainwright reduced their price target on shares of Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday, November 13th. Evercore ISI reissued an “in-line” rating and issued a $5.00 price target (down previously from $7.00) on shares of Savara in a research report on Wednesday, November 13th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $9.00 target price on shares of Savara in a report on Tuesday, October 1st. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $10.17.

Savara Stock Up 3.7 %

The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. The stock has a 50-day moving average of $3.80 and a two-hundred day moving average of $4.15. The company has a market cap of $556.91 million, a P/E ratio of -7.55 and a beta of 1.02.

Savara (NASDAQ:SVRA) last released its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.11). On average, research analysts anticipate that Savara Inc will post -0.45 EPS for the current fiscal year.

Institutional Trading of Savara

Institutional investors have recently made changes to their positions in the stock. CANADA LIFE ASSURANCE Co bought a new stake in shares of Savara in the 1st quarter worth approximately $35,000. Choreo LLC bought a new stake in Savara during the 2nd quarter valued at about $59,000. DRW Securities LLC purchased a new position in Savara in the 2nd quarter worth approximately $62,000. Virtu Financial LLC purchased a new position in shares of Savara in the third quarter worth $67,000. Finally, Principal Financial Group Inc. lifted its stake in Savara by 64.4% during the 2nd quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock valued at $72,000 after acquiring an additional 6,973 shares during the period. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.